ArticlePhytotherapy research : PTR2026
6-Shogaol Attenuates Doxorubicin-Induced Cardiac and Skeletal Muscle Atrophy by Inhibiting E3 Ubiquitin Ligases and Necroptosis.
Article in Phytotherapy research : PTR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Doxorubicin (DOX) is an effective anticancer agent, but it not only induces dose-dependent cardiotoxicity but also causes severe cardiac and skeletal muscle atrophy. Recent studies have indicated that cardiac atrophy may play an important role in DOX-induced cardiotoxicity. However, the mechanisms responsible for DOX-induced cardiac and skeletal muscle atrophy remain unclear. 6-Shogaol (6-SH) is a bioactive component from ginger, which exhibits various bioactive effects and can alleviate cisplatin-induced cachexia. In this work, we systematically assessed the effects of DOX and/or 6-SH on heart and skeletal muscle, as well as the underlying mechanisms. C57BL/6 mice were treated with DOX (5 mg/kg/3d, 4 doses, intraperitoneal) and given high or low doses of 6-SH (10/2.5 mg/kg, qd, intraperitoneal) for 14 days. Body weight, skeletal muscle mass, heart mass, grip strength, food intake and cardiac function were significantly reduced in DOX-treated mice, with these impairments notably ameliorated by 6-SH. Unexpectedly, 6-SH synergistically enhanced the antitumor efficacy of DOX. The DOX-induced significant decline in mitochondrial levels and slow-to-fast fiber type shift in skeletal muscle were notably attenuated by 6-SH treatment. Meanwhile, 6-SH exerted a protective effect against DOX-induced increases in cardiac oxidative stress, cardiac injury markers and inflammatory cytokines. DOX significantly upregulated the E3 ubiquitin ligases Atrogin1 and MuRF1 and downregulated MyoD and MyoG in the heart and skeletal muscle. Furthermore, DOX activated necroptosis, as evidenced by increased phosphorylation of receptor-interacting protein kinase (RIPK) 1, RIPK3, and mixed-lineage kinase domain-like (MLKL). 6-SH negatively regulated E3 ubiquitin ligases and necroptosis, while upregulating myogenic regulatory factors. In conclusion, 6-SH attenuated DOX-induced cardiac atrophy, skeletal muscle atrophy and cardiotoxicity by inhibiting E3 ubiquitin ligases and necroptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.